Minimal Clinically Important Difference of the Sinonasal Outcome Test in Sinonasal Malignancy

Key Points

• The study aims to estimate the minimal clinically important difference (MCID) of the Sinonasal Outcome Test for patients with sinonasal malignancy.
• Estimated MCID using data from a large multi-center cohort of patients with sinonasal malignancy.
• Analyzed quality of life changes.
• Identified predictors of quality of life outcomes.
• The estimated MCID of the SNOT-22 was 4.22.
• Advanced stage of malignancy and neck disease treatment predicted worse quality of life outcomes.
• Patients not receiving neoadjuvant therapy experienced different quality of life changes.